Almac Group Limited Company Profile
Integrated Solutions from Research to Commercialisation.
Almac is a financially secure, privately owned organisation with over 3,300 employees located within the US and UK. Over 600 companies worldwide, including all the market leaders, use our services, testament itself to the quality, innovation and efficiency of our business as proven over the past 30+ years.
Our vast range of services include:
Biomarker Discovery & Development: Pre-clinical biomarker discovery, through to full companion diagnostic development and clinical test delivery from our CLIA laboratory.
API Services & Chemical Development: Services for all stages of drug development for small molecules, potent and cytotoxic compounds and peptides.
Pharmaceutical Development: Developing clinical candidates into an optimum formulation and manufacturing drug product for all phases of clinical trial supply.
Analytical Services: Delivering comprehensive solutions supporting drug substance and product development programmes.
Clinical Trial Supply: Offering over 20 years experience in clinical supply, packaging, distribution and management.
Clinical Technologies: Providing interactive voice and web response technologies, flexible solutions for patient enrollment, electronic PROs and adaptive trials.
Commercial Services: Services for all drug products from manufacturing, testing and packaging to end-user distribution.
Almac – Partnering to Advance Human Health™
20 Seagoe Industrial Estate
Phone: +44 (0) 28 3833 2200
Almac has added new blistering technology at their US packaging facility in Audubon, PA, as a solution to ease the transition between clinical and commercial launch of blister products.
Almac has added new blistering technology at its US commercial packaging facility.
As part of an effort to ease the transition between clinical and commercial launch for blister products, Almac has added new blistering technology at its US commercial packaging facility in Audubon,...
Almac introduces a new [14C]-labelled antibody drug conjugate service to support the development of targeted drug treatments.
Genomic Health, Inc and Almac Group have established an agreement in which Genomic Health will exclusively license Almac’s technology and intellectual property to further develop, validate and comme...
Genomic Health, a provider of genomic-based diagnostic tests, will exclusively license Almac Group’s technology and intellectual property to further develop, validate and subsequently commercialize...
Genomic Health Inc. licensed rights to fellow cancer testing company Almac Diagnostics’ technology and IP related to the further development of a genomics-based product that will predict the likelih...
Almac’s Diagnostics business unit today announced the publication of its breast cancer chemotherapy response assay in the Journal of the National Cancer Institute (
Drugs and Medications
Humans demonstrate a clear bias toward members of their own group over members of other groups in a variety of ways. It has been argued that the motivation underlying this in-group bias in adults may...
To determine the associations between isoflavone (49.72% genistin, 5.32% daidzin, 34.54% glycitin) and breast cancer risk, 150 rats were given 5 mg 7,12-dimethylbenz(a)anthracene and half of them wer...
Residents (n=114) in the department of psychiatry at the University of Toronto were surveyed in the spring of 1987 about their training in and attitudes about group psychotherapy. Significant interest...
The study has been undertaken as number of sickle cell patients in Chhattisgarh tribal population is 23.7 %. The Co enzyme Q10 is a strong antioxidant and energy producing compound. The patients were...
[Purpose] The aim of this study was to clarify the effects of the ROM exercise on joint components according to histopathological analysis. [Subjects and Methods] In total, twenty-six 9-week-old adult...
The purpose of this study is to determine whether there is benefit from providing cognitive rehabilitation in the group setting. Several standardized tools will be used to measure progres...
Assessing OCD before and after group therapy
The purpose of this study is to determine whether cognitive-behavioral group prevention (CBT-G) for german children is effective and to what extent parental group training moderates outcom...
The purpose of the study is to verify superiority of the lafutidine group over the placebo group and non-inferiority to the famotidine group in terms of endoscopic healing rate of the pati...
To compare the clinical efficacy of donepezil between the naive group and the switching group.
Integrated Solutions from Research to Commercialisation. Almac is a financially secure, privately owned organisation with over 3,300 employees located within the US and UK. Over 600 companies world...
W2 Group is a global marketing services ecosystem that helps CMOs in their new role as builders of communities and content aggregators. W2 Group companies, including Digital...
PharmEvo is backed by a reputable corporate group with a history of successful business ventures spread over 30 years. The group made its debut in 1971, with the sales and marketing of prestigious bra...
Celebrating 25 years of insuring progress, the ACE Group is a global leader in insurance and reinsurance serving a diverse group of clients. Headed by ACE Limited (NYSE:ACE), a co...
The Man Group has its origins over 200 years ago in a broking business founded by James Man and was floated on the London Stock Exchange in 1994. Man Group plc trades on the London Stock Exchange (EMG...
More Information about "Almac Group Limited" on BioPortfolio
We have published hundreds of Almac Group Limited news stories on BioPortfolio along with dozens of Almac Group Limited Clinical Trials and PubMed Articles about Almac Group Limited for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Almac Group Limited Companies in our database. You can also find out about relevant Almac Group Limited Drugs and Medications on this site too.